Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women

References

• Beral V, Banks E, Reeves G, et al. Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat 1999;4:191–200
   PubMedGoogle Scholar
• Santen R, Pinkerton J, McCartney C, et al. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab 2001;86:16–23
   PubMed Web of Science ®Google Scholar
• Lando JF, Heck KE, Brett KM. Hormone replace-ment therapy and breast cancer risk in a nation-ally representative cohort. Am J Prey Med 1999; 17:176–80
   Google Scholar
• Bush T, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 2001;98: 498–508
   Google Scholar
• Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen—progestin replacement therapy and breast cancer risk. J Am Med Assoc 2000;283:485–91
   PubMed Web of Science ®Google Scholar
• Ross R, Paganini-Hill A, Wan P, et al. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328–32
   PubMed Web of Science ®Google Scholar
• Colditz G, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol 2000;152:950–64
   PubMed Web of Science ®Google Scholar
• Magnusson C, Baron J, Correia N, et al. Breast cancer risk following long-term oestrogen and oestrogen—progestin replacement therapy. Int J Cancer 1999;81:339–44
   PubMed Web of Science ®Google Scholar
• Chen CL, Weiss NS, Newcomb P, et al. Hormone replacement therapy in relation to breast cancer. J Am Med Assoc 2002;287:734–41
   PubMed Web of Science ®Google Scholar
• Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study follow-up (HERS II). J Am Med Assoc 2002;288: 58–66
   Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 2002;288:321–33
   Google Scholar
• National Toxicology Program Board of Scientific Counselors. Report on carcinogens background document for steroidal estrogens. US Department of Health and Human Services, Washington, DC, December, 2000
   Google Scholar
• Seeger H, Mueck AO, Lippert TH. Effect of norethisterone acetate on estrogen metabolism in postmenopausal women. Horm Metab Res 2000; 32:436–9
   Google Scholar
• Coldham NG, James VHT. A possible mecha-nism for increased breast cell proliferation by progestins through increased reductive 170-hydroxysteroid dehydrogenase activity. Int J Cancer 1990;45:174–8
   PubMed Web of Science ®Google Scholar
• Gunnarsson C, Olsson BM, Stal 0, et al. Abnor-mal expression of 170-hydroxysteroid dehydro-genase in breast cancer predicts late recurrence. Cancer Res 2001;61: 8448–51
   Google Scholar
• O'Brien SN, Anandjiwala J, Price TM. Differ-ences in the estrogen content of breast adipose tissue in women by menopausal status and hormone use. Obstet Gynecol 1997;90:244–8
   PubMed Web of Science ®Google Scholar
• Hofseth u, Raafat AM, Osuchi JR, et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate isin the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559–65
   PubMed Web of Science ®Google Scholar
• Bongard V, Ferrieres J, Ruidavets JB, et al. Transdermal estrogen replacement therapy and plasma lipids in 693 French women. Maturitas 1998;30:265–72
   PubMed Web of Science ®Google Scholar
• Coulam C, Acacio BD, Hodis FIN, et al. Correlation between plasma estradiol and
   Google Scholar
• Breslow NE, Day NE. Statistical Methods in
   Google Scholar
• Preston DL, Lubin JH, Pierce DA, McConney ME. EPICURE. Generalized Regression Models
   Google Scholar
• Cox DR. Regressions models and life table. J R Stat Soc 1972;34:187–220
   Google Scholar
• De Vathaire F, Koscielny S, Rezvany A, et al. Estimation de PIncidence des Cancers en France 1983–1987. Paris: INSERM, 1996
   Google Scholar
• Lippert C, Seeger H, Wallwiener D, Mueck AO. Effect of medroxyprogesterone acetate and norethisterone on the estradiol-stimulated prolif-eration of MCF-7 cells. Med Sci Res 1999;27: 595–6
   Google Scholar
• Malet C, Spritzer P, Guillaumin D, Kuttenn F. Progesterone effect on cell growth, ultra-structural aspect and estradiol receptors of normal human breast epithelial cells in culture. J Steroid Biochem 2000;73:171–81
   Google Scholar
• Pollow K, Boquoi E, Baumann J, et al. Compari-son of the in vitro conversion of estradiol-17f3 to estrone of normal and neoplastic human breast. Mol Cell Endocrinol 1977;6:333–48
   PubMed Web of Science ®Google Scholar
• Fournier S, Kuttenn F, DeCicco F, et al. Estradiol 170-hydroxysteroid dehydrogenase activity in human breast fibroadenomas. J Clin Endocrinol Metab 1982;55:428–33
   PubMed Web of Science ®Google Scholar
• Chang KJ, Fournier S, Lee TTY, et al. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril 1995;63:785–91
   PubMed Web of Science ®Google Scholar
• Willett WC, Colditz G, Stampfer M. Post-menopausal estrogens — opposed, unopposed, or none of the above. J Am Med Assoc 2000; 283:534–5
   Google Scholar
• Salmon RJ, Ansquer Y, Asselain B, et al. Clinical and biological characteristics of breast cancers in post-menopausal women receiving hormone replacement therapy for menopause. Oncol Rep 1999;6:699–703
   PubMed Web of Science ®Google Scholar
• Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, et al. Effects of oral and transdermal estrogen/ progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. Arterio-scler Thromb Vasc Biol 1997;17:3071–8
   PubMed Web of Science ®Google Scholar
• Marque V, Alhenec-Gelas M, Plu-Bureau G, Oger E, Scarabin PY. The effects of transdermal and oral estrogen/progesterone regimens on free and total protein S in postmenopausal women. Thromb Haemost 2001;86:713–14
   PubMed Web of Science ®Google Scholar